User profiles for Manaf AlQahtani

Manaf alqahtani

Professor of Medicine
Verified email at rcsi-mub.com
Cited by 2650

[HTML][HTML] COVID-19 and sickle cell disease in Bahrain

…, M Shabaan, S Otoom, SL Atkin, M AlQahtani - International journal of …, 2020 - Elsevier
Introduction Coronavirus disease 2019 (COVID-19) is caused by the newly identified strain
of the coronavirus family that has been shown to affect the hemoglobin beta chain, the same …

Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial

N Al Kaabi, Y Zhang, S Xia, Y Yang, MM Al Qahtani… - Jama, 2021 - jamanetwork.com
Importance Although effective vaccines against COVID-19 have been developed, additional
vaccines are still needed. Objective To evaluate the efficacy and adverse events of 2 …

[HTML][HTML] Plasmid-mediated colistin resistance in Escherichia coli from the Arabian Peninsula

Á Sonnevend, A Ghazawi, M Alqahtani, A Shibl… - International Journal of …, 2016 - Elsevier
Objectives Searching for the presence of the mcr-1 gene in colistin resistant Enterobacteriaceae
in countries of the Arabian Peninsula. Methods Seventy-five independent, colistin …

Recent advances in vaccine and immunotherapy for COVID-19

…, LH Al-Jamea, A Woodman, M Al-Qahtani… - Human vaccines & …, 2020 - Taylor & Francis
The COVID-19 pandemic caused by SARS-CoV-2 has resulted in millions of cases and
hundreds of thousands of deaths. Beyond there being no available antiviral therapy, stimulating …

[HTML][HTML] COVID-19 and mucormycosis superinfection: the perfect storm

…, AA Rabaan, A Al-Omari, R Tirupathi, M AlQahtani… - Infection, 2021 - Springer
Background The recent emergence of the Coronavirus Disease (COVID-19) disease had
been associated with reports of fungal infections such as aspergillosis and mucormycosis …

[HTML][HTML] Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

M AlQahtani, A Abdulrahman, A Almadani, SY Alali… - Scientific reports, 2021 - nature.com
Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in
severe disease. This pilot study was undertaken to inform feasibility and safety of further …

[HTML][HTML] Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical …

…, MM Alejandria, RN Alfonso, M Ali, M AlQahtani… - BMC infectious …, 2021 - Springer
Background Convalescent plasma has been widely used to treat COVID-19 and is under
investigation in numerous randomized clinical trials, but results are publicly available only for a …

Airborne transmission of SARS-CoV-2 is the dominant route of transmission: droplets and aerosols

…, JA Al-Tawfiq, A Al-Omari, AM Al-Qaaneh, M AlQahtani… - 2022 - repository.rcsi.com
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has become a pandemic worldwide. On a daily basis the number of …

[HTML][HTML] The high prevalence of asymptomatic SARS-CoV-2 infection reveals the silent spread of COVID-19

…, NJ Stevenson, SL Atkin, MM AlQahtani - International journal of …, 2021 - Elsevier
Purpose The COVID-19 pandemic has led to over 92 million cases and 1.9 million deaths
worldwide since its outbreak. Public health responses have focused on identifying …

[HTML][HTML] COVID-19: breaking down a global health crisis

…, B Atallah, R El-Lababidi, M Al-Qahtani - Annals of clinical …, 2021 - Springer
Coronavirus disease 2019 (COVID-19) is the second pandemic of the twenty-first century, with
over one-hundred million infections and over two million deaths to date. It is a novel strain …